Quantitative hepatitis B core antibody levels in the natural history of hepatitis B virus infection.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Clinical Microbiology and Infection

• Publication date

  2015-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.cmi.2014.10.002PMID 25658546
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Influence of mutations in hepatitis B virus surface protein on viral antigenicity and phenotype in occult HBV strains from blood donors.

  2012cited by this paper
• EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.

  2012cited by this paper
• Quantitative hepatitis B core antibody level may help predict treatment response in chronic hepatitis B patients

  2012cited by this paper
• [Updates of EASL clinical practice guidelines: management of chronic hepatitis B virus infection].

  2012cited by this paper
• Determinants of spontaneous surface antigen loss in hepatitis B e antigen–negative patients with a low viral load

  2012cited by this paper
• Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir

  2011cited by this paper
• Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters.

  2011cited by this paper
• Early on‐treatment prediction of response to peginterferon alfa‐2a for HBeAg‐negative chronic hepatitis B using HBsAg and HBV DNA levels

  2010cited by this paper
• Novel Double-Antigen Sandwich Immunoassay for Human Hepatitis B Core Antibody

  2010cited by this paper
• The natural history of chronic hepatitis B virus infection

  2009cited by this paper
• Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa‐2a in HBeAg‐negative patients

  2009cited by this paper
• Immunology of hepatitis B virus and hepatitis C virus infection

  2005cited by this paper
• Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis.

  2004cited by this paper
• Atlas of Gastroenterology

  2004cited by this paper
• A large population study of spontaneous HBeAg seroconversion and acute exacerbation of chronic hepatitis B infection: implications for antiviral therapy

  2003cited by this paper
• Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B

  1999cited by this paper
• Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen.

  1978cited by this paper

• Serology change-based clinical interpretation of indeterminate serostatus post-hepatitis B virus infection in people living with HIV

  2025cites this paper
• HBc: the multifunctional architect of HBV replication, immune evasion, and therapeutic innovation

  2025cites this paper
• Clinical performance of the Abbott Alinity anti-HBc immunoassay and its association with FIB-4 score in risk stratification of liver fibrosis.

  2025cites this paper
• Value and Kinetics of Virological Markers in the Natural Course of Chronic Hepatitis D Virus Infection

  2025cites this paper
• Update on the treatment navigation for functional cure of chronic hepatitis B: Expert consensus 2.0

  2025cites this paper
• Anti-HBc mirrors the activation of HBV-specific CD8+ T cell immune response and exhibits a direct effect on HBV control.

  2024cites this paper
• Association of Hepatitis B Surface Antigen Levels With Long‐Term Complications in Chronic Hepatitis B Virus Infection: A Systematic Literature Review

  2024cites this paper
• Newer Diagnostic Virological Markers for Hepatitis B Virus Infection

  2024cites this paper
• Clinical Features and Transition of Acute Hepatitis B Virus Infection

  2024cites this paper
• Assessment of Liver Fibrosis in HBsAg-Negative and Anti HBc Positive Patients

  2024cites this paper
• Association of hepatitis B core antibody level and hepatitis B surface antigen clearance in HBeAg-negative patients with chronic hepatitis B

  2024cites this paper
• HBsAg (−)/HBsAb (−)/HBeAg (−)/HBeAb (+)/HBcAb (+) predicts a high risk of hepatitis B reactivation in patients with B‐cell lymphoma receiving rituximab based immunochemotherapy

  2023cites this paper
• Predictive value of hepatitis B serological indicators for mortality among cancer survivors and validation in a gastric cancer cohort

  2023cites this paper
• Steady Decline of HBV DNA Load under NAs in Lymphoma Patients and a Higher Level of qAnti-HBc Predict HBV Reactivation

  2023cites this paper
• Impact of core protein naturally selected mutants associated with HBeAg‐negative status in HBV biosynthesis

  2023cites this paper
• Anti-HBc: a significant host predictor of spontaneous HBsAg seroclearance in chronic hepatitis B patients - a retrospective longitudinal study

  2023cites this paper
• Factors associated with persistent positive in HBV DNA level in patients with chronic Hepatitis B receiving entecavir treatment

  2023influential citation
• Hepatitis B Core Antibody Level: A Surrogate Marker for Host Antiviral Immunity in Chronic Hepatitis B Virus Infections

  2023cites this paper
• Modification of clinical indicators for differentiating stages of chronic HBV infection based on pathological changes in liver tissue

  2023cites this paper
• Clinical Utility of Quantitative HBV Core Antibodies for Solving Diagnostic Dilemmas

  2023influential citation
• A novel model based on qAnti-HBc and conventional biomarkers for identifying significant liver injury among CHB patients with ALT ≤ ULN.

  2022cites this paper
• The Origin of Capsid-Derived Immune Complexes and Their Impact on HBV-Induced Liver Diseases

  2022cites this paper
• Viral Diagnosis of Hepatitis B and Delta: What We Know and What Is Still Required? Specific Focus on Low- and Middle-Income Countries

  2022cites this paper
• Low anti‐HBc levels are associated with lower risk of virological relapse after nucleos(t)ide analogue cessation in HBe antigen‐negative patients

  2022cites this paper
• Quantitative anti-HBc combined with quantitative HBsAg can predict HBsAg clearance in sequential combination therapy with PEG-IFN-α in NA-suppressed chronic hepatitis B patients

  2022cites this paper
• Review article: novel biomarkers in hepatitis B infection

  2022cites this paper
• Virological Treatment Monitoring for Chronic Hepatitis B

  2022cites this paper
• Levels of Antibodies to Hepatitis B Core Antigen Are Associated With Liver Inflammation and Response to Peginterferon in Patients With Chronic Hepatitis B

  2022cites this paper
• Serum qAnti‐HBc combined with ALT and HBsAg predicts significant hepatic inflammation in HBeAg‐positive immune active patients

  2022cites this paper
• Dose–response relationship between qAnti‐HBc and liver inflammation in chronic hepatitis B with normal or mildly elevated alanine transaminase based on liver biopsy

  2022cites this paper
• Protective Role of Rheumatic Diseases Against Hepatitis B Virus Infection and Human Leukocyte Antigen B27 Highlighted

  2022cites this paper
• Higher titer hepatitis B core antibody predicts a higher risk of liver metastases and worse survival in patients with colorectal cancer

  2021cites this paper
• A noninvasive model to predict liver histology for antiviral therapy decision in chronic hepatitis B with alanine aminotransferase < 2 upper limit of normal

  2021cites this paper
• Anti-HBc IgG Levels: A Predictor of HBsAg Seroclearance in Chronic Hepatitis B Patients with Nucleos(t)ide Analogue-Induced HBeAg Seroclearance

  2021cites this paper
• Hepatitis B core-related antigen reflects viral replication and protein production in chronic hepatitis B patients

  2021influential citation
• Efficacy of Antiviral Treatment in Liver Biopsy-Proven Immune-Tolerant Chronic Hepatitis B Patients: A Retrospective Cohort Study

  2021cites this paper
• Resolved Hepatitis B: Achieved or Imaginary Wellbeing?

  2021cites this paper
• Novel Biomarkers of Hepatitis B Virus and Their Use in Chronic Hepatitis B Patient Management

  2021influential citation
• Prediction of hepatic inflammation in chronic hepatitis B patients with a random forest-backward feature elimination algorithm

  2021cites this paper
• Significant Histologic Changes Are Not Rare in Treatment-naive Hepatitis B Patients with Normal Alanine Aminotransferase Level: A Meta-analysis

  2021cites this paper
• Baseline quantitative HBcAb strongly predicts undetectable HBV DNA and RNA in chronic hepatitis B patients treated with entecavir for 10 years

  2021cites this paper
• Quantitative serum HBV markers in predicting phases of natural history of chronic HBV infection.

  2021cites this paper
• Expression and clinical significance of inhibitory receptor Leukocyte-associated immunoglobulin-like receptor-1 on peripheral blood T cells of chronic hepatitis B patients

  2021cites this paper
• Baseline serum hepatitis B core antibody level predicts HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B after antiviral treatment.

  2021cites this paper
• Association of anti‐HBc and liver inflammation in HBeAg‐negative chronic hepatitis B virus‐infected patients with normal ALT and detectable HBV DNA

  2021cites this paper
• Viral and Host Factors Affecting Disease Progression of Hepatitis B Virus Infection

  2021cites this paper
• Novel Biomarkers for the Management of Chronic Hepatitis B Virus Infection

  2021cites this paper
• Baseline Quantitative Hepatitis B Core Antibody Titer Is a Predictor for Hepatitis B Virus Infection Recurrence After Orthotopic Liver Transplantation

  2021cites this paper
• Guidelines for Prevention and Treatment of Chronic Hepatitis B

  2021cites this paper
• How to interpret viral markers in the management of chronic hepatitis B infection.

  2021cites this paper
• A baseline model including quantitative anti-HBc to predict response of peginterferon in HBeAg-positive chronic hepatitis B patients

  2021cites this paper
• Humoral immunity in hepatitis B virus infection: Rehabilitating the B in HBV

  2021cites this paper
• Title: Higher Titer Hepatitis B Core Antibody Predicts a Higher Risk of Liver Metastasis and Worse Survival in Patients with Colorectal Cancer Short title: Anti-HBc Predicts Prognosis of CRC

  2021influential citation
• Biomarkers for hepatitis B virus replication: an overview and a look to the future

  2020cites this paper
• Analytical and clinical evaluation of a novel assay for anti-HBc IgG measurement in serum of subjects with overt and occult HBV infection.

  2020cites this paper
• Kinetics of hepatitis B core-related antigen and anti-hepatitis B core antibody and their association with serological response in HIV-hepatitis B co-infection.

  2020cites this paper
• Isolated Anti-HBc: Significance and Management

  2020cites this paper
• Cryptic HBV Replicative Activity Is Frequently Revealed in Anti-HBc-Positive/HBsAg-Negative Patients with HIV Infection by Highly Sensitive Molecular Assays, and Can Be Predicted by Integrating Classical and Novel Serological HBV Markers

  2020cites this paper
• Control of Chronic Hepatitis B in China: Perspective of Diagnosis and Treatment

  2020cites this paper
• Prognostic value of anti‐HBc quantification in hepatitis B virus related acute‐on‐chronic liver failure

  2020cites this paper
• Combination of quantitative hepatitis B core antibody (qHBcAb) and aspartate aminotransferase (AST) can accurately diagnose immune tolerance of chronic hepatitis B virus infection based on liver biopsy.

  2020cites this paper
• Moving towards core antigen for the management of patients with overt and occult HBV infection.

  2020cites this paper
• The hepatitis B core antibody positive/hepatitis B surface antigen negative pattern is associated with the increased risk of intracranial atherosclerotic stenosis

  2020cites this paper
• Hepatitis B Core Antibody: Role in Clinical Practice in 2020

  2020cites this paper
• Association of Hepatitis B Core-Related Antigen and Antihepatitis B Core Antibody With Liver Fibrosis Evolution in Human Immunodeficiency Virus-Hepatitis B Virus Coinfected Patients During Treatment With Tenofovir

  2020cites this paper
• Clinical relevance of the in situ assay for HBV DNA: a cross-sectional study in patients with chronic hepatitis B

  2020cites this paper
• Clinical features of hepatitis B patients at immune‐tolerance phase with basal core promoter and/or precore mutations

  2020cites this paper
• Role of hepatitis B antibody in predicting reactivation of resolved hepatitis B virus infection in leukemia patients.

  2020cites this paper
• Hepatitis B core antibody and liver stiffness measurements predict HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients with minimally elevated alanine aminotransferase (ALT) levels

  2020cites this paper
• Prevalence of Hepatitis B Core Antibody in Medical Health care Workers in Nnewi, Anambra state, Nigeria

  2020cites this paper
• Role of Biomarkers in Guiding Cure of Viral Hepatitis B

  2019cites this paper
• Quantitative of serum hepatitis B core antibody is a potential predictor of recurrence after interferon-induced hepatitis B surface antigen clearance.

  2019cites this paper
• Monitoring of Serum HBV RNA, HBcrAg, HBsAg and anti-HBc Levels in Patients during Long-Term Nucleoside/Nucleotide Analogue Therapy

  2019cites this paper
• New and Old Biomarkers for Diagnosis and Management of Chronic Hepatitis B Virus Infection.

  2019cites this paper
• Quantitative Anti-HBc in Liver Pathological States in Patients with Chronic Hepatitis B Virus Infection

  2019cites this paper
• Baseline Level of Hepatitis B Core Antibody Predicts Spontaneous Hepatitis B e Antigen (HBeAg) Seroconversion in HBeAg‐Positive Children With a Normal Alanine Aminotransferase Level

  2019cites this paper
• Serum Level of Antibodies Against Hepatitis B Core Protein Is Associated With Clinical Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy

  2019cites this paper
• Level of Hepatitis B (HB) Core Antibody Associates With Seroclearance of HBV DNA and HB Surface Antigen in HB e Antigen‐Seronegative Patients

  2019cites this paper
• Non-invasive biomarkers for chronic hepatitis B virus infection management.

  2019cites this paper
• Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection.

  2018cites this paper
• Serum hepatitis B core antibody levels predict HBeAg seroconversion in chronic hepatitis B patients with high viral load treated with nucleos(t)ide analogs

  2018cites this paper
• A novel noninvasive index for the prediction of moderate to severe fibrosis in chronic hepatitis B patients.

  2018cites this paper
• Quantification of serum markers of hepatitis B (HBV) and Delta virus (HDV) infections in patients with chronic HDV infection

  2018cites this paper
• Distinct Relapse Rates and Risk Predictors After Discontinuing Tenofovir and Entecavir Therapy

  2018cites this paper
• Management of Hepatitis B Virus Infection: 2018 Guidelines from the Canadian Association for the Study of Liver Disease and Association of Medical Microbiology and Infectious Disease Canada.

  2018cites this paper
• Viral Factors Affecting Disease Progression

  2018cites this paper
• Clinical noninvasive markers for antiviral therapy decision in chronic hepatitis B with alanine aminotransferase less than two times upper limit of normal

  2018cites this paper
• Performance of Hepatitis B Core-Related Antigen Versus Hepatitis B Surface Antigen and Hepatitis B Virus DNA in Predicting HBeAg-positive and HBeAg-negative Chronic Hepatitis

  2018cites this paper
• Role of quantitative hepatitis B core antibody levels in predicting significant liver inflammation in chronic hepatitis B patients with normal or near‐normal alanine aminotransferase levels

  2018cites this paper
• A mouse model with age-dependent immune response and immune-tolerance for HBV infection.

  2018cites this paper
• New and Old Biomarkers for Diagnosis and Management of Chronic HBV Infection

  2018cites this paper
• Europium (III) chelate microparticle-based lateral flow immunoassay strips for rapid and quantitative detection of antibody to hepatitis B core antigen

  2017cites this paper
• Viral Factors Affecting the Clinical Outcomes of Chronic Hepatitis B

  2017cites this paper
• Tumor necrosis factor-α-induced protein 8-like 2 (TIPE2) is associated with immune phases of patients with chronic hepatitis B

  2017cites this paper
• Baseline hepatitis B core antibody predicts treatment response in chronic hepatitis B patients receiving long‐term entecavir

  2017cites this paper
• Current advances in the elimination of hepatitis B in China by 2030

  2017cites this paper
• Quantification of serum hepatitis B core antibody to predict off-entecavir relapse in patients with chronic hepatitis B.

  2017cites this paper
• Isolated anti-HBc: The Relevance of Hepatitis B Core Antibody—A Review of New Issues

  2017cites this paper
• Looking into the crystal ball: biomarkers for outcomes of HBV infection

  2016cites this paper
• Review of Laboratory Tests used in Monitoring Hepatitis B Response to Pegylated Interferon and Nucleos(t)ide Analog Therapy

  2016cites this paper